"What" Series

What is the Therapeutic Index (TI)?

26 April 2024
2 min read

The Therapeutic Index (TI) is an important parameter in assessing the safety of drugs. It is used to measure the relationship between the safety and effectiveness of a drug. The therapeutic index is typically calculated by comparing the minimum effective dose (MED) and the median lethal dose (LD50) of a drug, as follows:

Therapeutic Index (TI) = LD50/MED

Alternatively, sometimes the ratio of the LD50 to the median effective dose (ED50) is used to represent the therapeutic index:

Therapeutic Index (TI) = LD50/ED50

A higher therapeutic index indicates that a drug is safer because it means that the dose required to reach a toxic level is much higher than the dose required to produce a therapeutic effect. Conversely, if the therapeutic index is low, it suggests that the drug has a lower safety profile, as there is a smaller gap between the effective dose and the toxic dose, requiring more caution when using the drug.

In drug development and clinical application, the therapeutic index is an important reference indicator that helps doctors and pharmacologists assess the risks and benefits of a drug. However, it should be noted that the therapeutic index is not the only criterion for evaluating drug safety. Other factors such as the pharmacological properties of the drug, individual patient differences, and drug interactions should also be considered.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

EU Commission Approves Expanded Use of Astellas' XTANDI™ for Early-Stage Recurrent Prostate Cancer
Latest Hotspot
3 min read
EU Commission Approves Expanded Use of Astellas' XTANDI™ for Early-Stage Recurrent Prostate Cancer
26 April 2024
European Commission approves Astellas' XTANDI™ (Enzalutamide) for expanded use in recurrent early-stage prostate cancer treatment.
Read →
European Commission Approves FILSPARI® by CSL Vifor and Travere Therapeutics for IgA Nephropathy Treatment
Latest Hotspot
3 min read
European Commission Approves FILSPARI® by CSL Vifor and Travere Therapeutics for IgA Nephropathy Treatment
26 April 2024
CSL Vifor and Travere Therapeutics Report European Commission's Approval of FILSPARI® (sparsentan) for IgA Nephropathy Treatment.
Read →
FDA Approves OncoC4's IND for SIGLEC 10 Blocker ONC-841 Against Solid Tumors
Latest Hotspot
3 min read
FDA Approves OncoC4's IND for SIGLEC 10 Blocker ONC-841 Against Solid Tumors
26 April 2024
OncoC4 Reveals FDA Approval for Investigational New Drug Application of Its Unique SIGLEC 10 Immune Checkpoint Blocker, ONC-841, Targeting Solid Tumors.
Read →
hC Bioscience Unveils Hemophilia Project and Promising Results from tRNA Anticodon Strategy
Latest Hotspot
3 min read
hC Bioscience Unveils Hemophilia Project and Promising Results from tRNA Anticodon Strategy
26 April 2024
hC Bioscience Reveals Primary Project in Hemophilia and Shares Encouraging Early Results from Innovative Protein Modification Strategy Using Engineered tRNA Anticodons.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.